The binding sites obtained from both methods is displayed in (Figures and). The term "druggable/binding site" refers to the capacity of medications or ligands to target and bind to particular protein areas effectively. Developing therapies that bind to these macromolecules requires the identification of druggable/binding sites. The next stage was to predict the 3D structure of aptamers by using the Vfold2d and Vfold3d to make the 3D structure of aptamers clear . This study involved four aptamers: HB5 displays the aptamer sequences used in this study. The outer HB5 aptamers were docked on the HER2 receptor to find their interactions. The HB5aptamer docking was performed using the HDOCK2.4 software, Figure 2d . Their interactions were calculated by the PLIP software, as shown in Table . Based on the aptamer structure prediction and aptamer-HB5 binding, the mechanism of aptamer binding and functioning is shown in Figure . Aptamers that interact with the amino acids of the HER2 receptor are mostly present in the predicted binding site of the HER2 receptor. For instance, Asn416, Gln424, Gly425, His451, His415, His447, and His448 are present in the binding site of the HER2 receptor. On the other hand, only four amino acids, Ser259, Ala276, Cys277, and Gln462, were interacting with the HER2 receptor and are present in the binding site of the HER2 receptor, which shows that the HB5